{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:00:56Z","timestamp":1782748856879,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","award":["P30 CS042014"],"award-info":[{"award-number":["P30 CS042014"]}],"id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1 CA246716"],"award-info":[{"award-number":["RO1 CA246716"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jconrel.2024.10.062","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:48:40Z","timestamp":1731026920000},"page":"1014-1024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer"],"prefix":"10.1016","volume":"376","author":[{"given":"Jiahui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaden","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al Faruque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Galang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2024.10.062_bb0005","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1096\/fj.08-111005","article-title":"Life and death by death receptors","volume":"23","author":"Guicciardi","year":"2009","journal-title":"FASEB J."},{"issue":"21","key":"10.1016\/j.jconrel.2024.10.062_bb0010","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-12-3104","article-title":"Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008","volume":"19","author":"Burvenich","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","article-title":"TRAIL therapy and prospective developments for cancer treatment","volume":"326","author":"Thapa","year":"2020","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2024.10.062_bb0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/cancers11040456","article-title":"TRAILblazing strategies for cancer treatment","volume":"11","author":"Kretz","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"\u0160najdauf","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.jconrel.2024.10.062_bb0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"de Miguel","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0035","series-title":"Peptides for Youth","first-page":"101","author":"Angell","year":"2009"},{"issue":"7","key":"10.1016\/j.jconrel.2024.10.062_bb0040","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1021\/acs.nanolett.1c04469","article-title":"A high throughput approach for designing polymers that mimic the TRAIL protein","volume":"22","author":"Li","year":"2022","journal-title":"Nano Lett."},{"issue":"5","key":"10.1016\/j.jconrel.2024.10.062_bb0045","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/chem.201202415","article-title":"Multimerization of an apoptogenic TRAIL-mimicking peptide by using adamantane-based dendrons","volume":"19","author":"Lamanna","year":"2013","journal-title":"Chem. Eur. J."},{"issue":"3","key":"10.1016\/j.jconrel.2024.10.062_bb0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1158\/0008-5472.CAN-09-2889","article-title":"Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity","volume":"70","author":"Pavet","year":"2010","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.jconrel.2024.10.062_bb0055","doi-asserted-by":"crossref","first-page":"15566","DOI":"10.18632\/oncotarget.24526","article-title":"Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes","volume":"9","author":"Chekkat","year":"2018","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.jconrel.2024.10.062_bb0060","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/cbic.201900251","article-title":"TRAIL-inspired multivalent dextran conjugates efficiently induce apoptosis upon DR5 receptor clustering","volume":"20","author":"Schneider","year":"2019","journal-title":"Chembiochem"},{"issue":"6","key":"10.1016\/j.jconrel.2024.10.062_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1593\/neo.05823","article-title":"Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L\/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation","volume":"8","author":"Ziauddin","year":"2006","journal-title":"Neoplasia"},{"issue":"10","key":"10.1016\/j.jconrel.2024.10.062_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141610","article-title":"Limited effect of chronic valproic acid treatment in a mouse model of Machado-Joseph disease","volume":"10","author":"Esteves","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jconrel.2024.10.062_bb0075","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.yexcr.2012.02.005","article-title":"Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis","volume":"318","author":"Fulda","year":"2012","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biomaterials.2018.10.007","article-title":"Biorecognition: a key to drug-free macromolecular therapeutics","volume":"190-191","author":"Yang","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2024.10.062_bb0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/nn4053827","article-title":"Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis","volume":"8","author":"Chu","year":"2014","journal-title":"ACS Nano"},{"issue":"15","key":"10.1016\/j.jconrel.2024.10.062_bb0090","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.3390\/molecules26154658","article-title":"Crosslinking of CD38 receptors triggers apoptosis of malignant B cells","volume":"26","author":"Gambles","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0095","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jconrel.2022.08.045","article-title":"Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo","volume":"350","author":"Gambles","year":"2022","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2024.10.062_bb0100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7150\/thno.12040","article-title":"A two-step pretargeted nanotherapy for CD20 crosslinking may achieve superior anti-lymphoma efficacy to rituximab","volume":"5","author":"Chu","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0105","series-title":"Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine, Nanomedicine: NBM","first-page":"217","volume":"vol. 16","author":"Wang","year":"2019"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0110","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s13346-024-01629-3","article-title":"Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and\/or CD38 receptors","volume":"14","author":"Li","year":"2024","journal-title":"Drug Deliv. Translat. Res."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1021\/bm201656k","article-title":"Biological activity of anti-CD20 multivalent HPMA copolymer-Fab\u2019 conjugates","volume":"13","author":"Johnson","year":"2012","journal-title":"Biomacromolecules"},{"issue":"29","key":"10.1016\/j.jconrel.2024.10.062_bb0120","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1016\/j.biomaterials.2012.06.024","article-title":"Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis","volume":"33","author":"Chu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2016.12.025","article-title":"Drug-free macromolecular therapeutics: impact of structure on induction of apoptosis in Raji B cells","volume":"263","author":"Zhang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.062_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jconrel.2021.01.016","article-title":"Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages","volume":"331","author":"Je","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2024.10.062_bb0135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev."},{"issue":"12","key":"10.1016\/j.jconrel.2024.10.062_bb0140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.trecan.2020.06.006","article-title":"TRAIL of hope meeting resistance in cancer","volume":"6","author":"Deng","year":"2020","journal-title":"Trends in Cancer"},{"issue":"50","key":"10.1016\/j.jconrel.2024.10.062_bb0145","doi-asserted-by":"crossref","first-page":"43383","DOI":"10.1074\/jbc.M111.309377","article-title":"Importin \u03b21 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5\/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells","volume":"286","author":"Kojima","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2024.10.062_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.423","article-title":"Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells","volume":"8","author":"Shlyakhtina","year":"2017","journal-title":"Cell Death Dis."},{"issue":"37","key":"10.1016\/j.jconrel.2024.10.062_bb0155","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/sj.onc.1207830","article-title":"Histone deacetylase inhibitors upregulate death receptor 5\/TRAIL-R2 and sensitize apoptosis induced by TRAIL\/APO2-L in human malignant tumor cells","volume":"23","author":"Nakata","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jconrel.2024.10.062_bb0160","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Xia","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720981878","article-title":"Valproic acid enhanced apoptosis by promoting autophagy via Akt\/mTOR signaling in glioma","volume":"29","author":"Han","year":"2020","journal-title":"Cell Transplant."},{"issue":"12","key":"10.1016\/j.jconrel.2024.10.062_bb0170","doi-asserted-by":"crossref","first-page":"1908961","DOI":"10.1002\/adfm.201908961","article-title":"Inhibition of immunosuppressive tumors by polymer-assisted inductions of immunogenic cell death and multivalent PD-L1 crosslinking","volume":"30","author":"Li","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2024.10.062_bb0175","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/anie.200906232","article-title":"Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil mediated crosslinking of antigens on cell surface","volume":"49","author":"Wu","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.jconrel.2024.10.062_bb0180","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/pharmaceutics13091413","article-title":"Amphiphilic poly(N-vinylpyrrolidone) nanoparticles conjugated with DR5-specific antitumor cytokine DR5-B for targeted delivery to cancer cells","volume":"13","author":"Yagolovich","year":"2021","journal-title":"Pharmaceutics"},{"issue":"50","key":"10.1016\/j.jconrel.2024.10.062_bb0185","doi-asserted-by":"crossref","first-page":"19823","DOI":"10.1021\/jacs.9b09899","article-title":"A dual wavelength polymerization and bioconjugation strategy for high throughput synthesis of multivalent ligands","volume":"141","author":"Li","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.jconrel.2024.10.062_bb0190","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jmb.2006.06.042","article-title":"Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists","volume":"361","author":"Li","year":"2006","journal-title":"J. Mol. Biol."},{"issue":"31","key":"10.1016\/j.jconrel.2024.10.062_bb0195","doi-asserted-by":"crossref","first-page":"22093","DOI":"10.1021\/jacs.4c08658","article-title":"Collapsed star copolymers exhibiting near perfect mimicry of the therapeutic protein \"TRAIL\"","volume":"146","author":"Han","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2024.10.062_bb0200","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"issue":"44","key":"10.1016\/j.jconrel.2024.10.062_bb0205","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/onc.2011.614","article-title":"Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP","volume":"31","author":"Bangert","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jconrel.2024.10.062_bb0210","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/msy.2001.115897","article-title":"Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis","volume":"130","author":"Hernandez","year":"2001","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.jconrel.2024.10.062_bb0215","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","article-title":"Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein","volume":"102","author":"Aron","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2024.10.062_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.cdd.4401507","article-title":"Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP","volume":"12","author":"Watanabe","year":"2005","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.jconrel.2024.10.062_bb0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.21054","article-title":"HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL","volume":"43","author":"Pathil","year":"2006","journal-title":"Hepatology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:38:02Z","timestamp":1733578682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924007351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"alternative-id":["S0168365924007351"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.062","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}